Incyte's Opzelura vitiligo data published in NEJM

Data on Incyte’s (Nasdaq: INCY) Opzelura (ruxolitinib) cream from the pivotal Phase III TRuE-V clinical trial program have been published in The New England Journal of Medicine (NEJM).

Following an earlier approval in atopic dermatitis, the novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib was approved in July this year by the US Food and Drug Administration (FDA) for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older.

"These data reinforce the potential that this new medical treatment can have for people who are interested in repigmentation"The data - which showed that the application of the cream resulted in significant facial and total body repigmentation versus vehicle-control at week 24 and a higher proportion of patients responding at week 52 - served as basis for the FDA approval.